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We reviewed the literature regarding the serum levels of the enzymes aspartate aminotransferase, alanine
aminotransferase, and gamma-glutamyl transferase in patients with chronic kidney disease on hemodialysis
with and without viral hepatitis.
Original articles published up to January 2013 on adult patients with chronic kidney disease on hemodialysis
were selected. These articles contained the words ‘‘transaminases’’ ‘‘aspartate aminotransferase’’ ‘‘alanine
aminotransferase’’ ‘‘gamma glutamyl transferase,’’ ‘‘liver enzymes’’, AND ‘‘dialysis’’ OR ‘‘hemodialysis’’.
A total of 823 articles were retrieved. After applying the inclusion and exclusion criteria, 49 articles were
selected. The patients with chronic kidney disease on hemodialysis had reduced serum levels of
aminotransferases due to hemodilution, lower pyridoxine levels, or elevated homocysteine levels. The chronic
kidney disease patients on hemodialysis infected with the hepatitis C virus also had lower aminotransferase
levels compared with the infected patients without chronic kidney disease. This reduction is in part due to
decreased viremia caused by the dialysis method, the production of a hepatocyte growth factor and
endogenous interferon-a, and lymphocyte activation, which decreases viral action on hepatocytes. Few studies
were retrieved on gamma-glutamyl transferase serum levels; those found reported that there were no
differences between the patients with or without chronic kidney disease.
The serum aminotransferase levels were lower in the patients with chronic kidney disease on hemodialysis
(with or without viral hepatitis) than in the patients with normal renal function; this reduction has a
multifactorial origin.
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& INTRODUCTION
The serum levels of the liver enzymes alanine amino-
transferase (ALT), aspartate aminotransferase (AST), and
gamma-glutamyl transferase (GGT) are markers of aggres-
sion against hepatocytes (1). Thus, they are elevated in
several diseases, such as chronic viral hepatitis (2), non-
alcoholic fatty liver disease (3), autoimmune hepatitis (4),
hemochromatosis (5), and alcoholic liver disease (6). These
enzymes assist in diagnosis and patient follow-up and
response to treatment because they reflect inflammatory
activity in the parenchyma of the liver (7–9).
The prevalence of hepatitis C virus (HCV) infection is
significantly higher in hemodialysis (HD) patients than in
the general population (10); this disease is associated with
an increased mortality rate primarily due to hepatocellular
carcinoma and liver cirrhosis (11,12). The prevalence of
HCV infection in HD patients varies greatly between
regions of the world and even within the same country
(13). The prevalence rates of hepatitis C are 5.5% for dialysis
patients in Brazil, 14.4% for those in the United States, and
68% for those in Saudi Arabia (13–15). Although HCV
infection results in an increase in ALT, these levels are
generally lower in hemodialysis patients.
Interestingly, some studies have shown that patients with
chronic kidney disease (CKD) on HD may have lower
serum levels of liver enzymes than those with normal renal
function for reasons that remain unclear (16,19). This profile
may adversely affect the diagnosis, clinical management,
and treatment of liver disease in these patients.
The objective of this study was to review the literature to
assess the serum levels of GGT and the reasons that favor
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lower levels of ALT and AST in CKD patients undergoing
HD. The evaluation of alkaline phosphatase was excluded
from this review because this enzyme has a ‘‘bone fraction’’
and is involved in the disturbances of bone mineral
metabolism that occur in CKD patients.
& METHODS
A review of the literature was performed using the
Medical Literature Analysis and Retrieval System Online
(MEDLINE), the Latin American and Caribbean Literature
on Health Sciences (LILACS), the Scientific Electronic
Library Online (SciELO), and the COCHRANE virtual
library. The searches were performed in December 2012
and January 2013.
For each search, a specific strategy was drawn up for
crosschecking the Medical Subject Headings (MeSH) terms
and the free terms (FTs) that were not found in MeSH but
were of relevance to the research.
The following descriptors were used separately: ‘‘hemo-
dialysis’’[All Fields] AND ‘‘liver enzymes’’[All Fields] AND
‘‘humans’’[MeSH Terms]; ‘‘hemodialysis’’[All Fields] AND
‘‘aspartate transaminase’’[All Fields] AND ‘‘humans’’[MeSH
Terms]; ‘‘hemodialysis’’[All Fields] AND ‘‘gamma-glutamyl-
transferase’’[All Fields] AND ‘‘humans’’[MeSH Terms];
‘‘hemodialysis’’[All Fields] AND ‘‘alanine transaminase’’
[All Fields] AND ‘‘humans’’[MeSH Terms]; ‘‘dialysis’’[All
Fields] AND ‘‘liver enzymes’’[All Fields] AND ‘‘humans’’
[MeSH Terms]; ‘‘dialysis’’[All Fields] AND ‘‘aspartate
transaminase’’[All Fields] AND ‘‘humans’’[MeSH Terms];
‘‘dialysis’’[All Fields] AND ‘‘gamma-glutamyltransferase’’
[All Fields] AND ‘‘humans’’[MeSH Terms]; ‘‘dialysis’’[All
Fields] AND ‘‘alanine transaminase’’[All Fields] AND
‘‘humans’’[MeSH Terms].
Selection criteria
The inclusion criteria required that the studies utilized
adult human patients with CKD on HD; that they had a
publication date prior to January 2013; and that they were
written in Portuguese, English or Spanish. Relevant articles
cited in the references of those initially selected were
also included. The exclusion criteria included articles that
involved patients with acute kidney injury; articles that
primarily described the prevalence, routes of transmission,
and treatment of hepatitis; articles reporting medicamen-
tous or exogenous toxicity or those involving transplant
patients. Articles with a primary focus on the treatment of
viral hepatitis were excluded because this treatment could
influence the aminotransferase serum levels and, therefore,
the physiopathological ‘‘non-elevation’’ of the relevant
enzymes.
& RESULTS
A total of 823 articles were retrieved. After reading the
title, 215 were excluded for not fitting the inclusion criteria.
Another 472 articles matched the exclusion criteria and were
removed from the analysis. Of the remaining 136 articles,
another 41 articles were excluded after reading the abstracts
(Figure 1). After this step, another 46 articles that were
repeated within databases were identified and excluded. A
total of 49 complete original articles were then analyzed. Of
these, 6 matched the exclusion criteria and were excluded,
leaving a total of 43 articles. Subsequently, 6 articles were
selected from the references of those already included
because they were considered relevant. This left a total of
49 articles.
Due to the heterogeneity of the studies and the
predominance of articles involving liver enzymes in patients
with viral hepatitis, the results were didactically divided
into two topics to enhance the understanding of the
analysis. One topic was on liver enzymes in CKD patients
on HD without hepatitis virus infection, and the other was
on the serum levels of the liver enzymes in patients with
such an infection.
& DISCUSSION
Liver enzymes in CKD patients on hemodialysis
Aminotransferases. Since the 1970s, studies have shown
that AST and ALT serum levels were decreased in CKD
patients undergoing HD. It was hypothesized that this
reduction could be caused by factors such as the withdrawal
of aminotransferases during the HD session; the high lactate
serum levels, which, during biochemical dosages, would
rapidly consume Nicotinamide Adenine Dinucleotide
Phosphate (NADPH) and result in low levels of amino-
transferases; the presence of uremic factors that would
inhibit the activity of these enzymes; and, finally, the
deficiency of pyridoxine, a cofactor for the synthesis of the
aminotransferases (20,21).
In assessing the possibility of this pyridoxine deficit, in
the 1980s, Jung et al. evaluated the levels of aminotrans-
ferases in CKD patients on HD and did not observe
differences between the values prior to and after the
addition of pyridoxal 59-phosphate (PLP), an active form
of pyridoxine, to the chemical reaction for the dosage of
these enzymes (18). Similarly, Gressner et al. evaluated 26
patients undergoing HD and found no relationship between
the fluctuations of the plasma levels of PLP (pPLP) and ALT
or AST serum levels (19).
Later, in the 1990s, Ono et al. performed a prospective
study in which they administered pyridoxine (30 mg/day)
to 52 CKD patients on HD for 5 weeks. Prior to
supplementation (Day 0), 17 patients (33%) had deficient
pPLP levels (Group 1), and the other 35 patients had normal
pPLP values (Group 2). There were positive correlations
between pPLP and AST levels (r = 0.57; p,0.01) and
between pPLP and ALT levels (r = 0.68; p,0.01). The mean
serum levels of AST (9.2¡0.3 vs. 13.4¡0.7 U/L) and ALT
(8.6¡0.6 vs. 11.4¡0.9 U/L) were significantly lower in
Group 1 than in Group 2. These researchers concluded that
the low AST and ALT levels in patients on HD were partly
due to a deficiency in pyridoxine, which serves as a
coenzyme in the synthesis of the aminotransferases (20).
However, Yasuda et al. did not find a serum deficiency of
pyridoxine in a group of 305 CKD patients on HD when
compared with 556 healthy individuals, thereby putting
the role of pyridoxine as a factor in the reduction of
aminotransferase serum levels to question. Nevertheless,
the average respective AST and ALT serum levels were
9.2¡2.4 and 7.4¡1.7 IU/L in those undergoing HD and
22.7¡5.4 and 18.0¡4,0 IU/L in healthy subjects (p,0.001 in
both comparisons).
Therefore, the only study that demonstrated an associa-
tion between pyridoxine and aminotransferase levels was
performed by Ono et al; this study was prospective and
interventional (20). However, the influence of pyridoxine in
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low serum aminotransferase levels remains uncertain, and
the largest and most recent study found no such association
(22). Therefore, a prospective double-blind randomized trial
has been proposed to evaluate the supplementation of
pyridoxine as a factor that influences the aminotransferase
levels in HD patients.
In this same study, Yasuda et al. collected serum
aminotransferases prior to and after HD sessions and
observed a 15-35% increase after dialysis, which supports
the hypothesis of hemoconcentration for the rise in
aminotransferases observed after the dialysis procedure
(22).
We have described an association between weight loss
(ultrafiltration) during HD and increased serum ALT levels
in 146 patients with CKD. The average weight loss in these
patients was 5.3%, and the mean ALT levels prior to and
after HD were 18.8 and 23.9 IU/L, respectively, an increase
of 28.1%. The weight loss was inversely correlated with
the increase in the ALT level (r = 0.3; p,0.001) (23).
Subsequently, this hypothesis was also corroborated by
Liberato et al., who found lower serum levels of ALT but
also of AST and GGT prior to HD compared with after HD
(16).
More recently, Sombolos et al.evaluated 53 CKD patients
on HD and divided them into three groups: HD, isolated
ultrafiltration, and euvolemic HD (without the removal of
fluids) and verified the effects of hemodilution in the serum
levels of the aminotransferases. In the patients who under-
went euvolemic HD, there were no differences between
the ALT and AST levels prior to and after the procedure.
However, when an isolated ultrafiltration or HD was
performed, there was an increase in the aminotransferase
levels when compared with the values prior to and after the
procedure (24). The authors concluded that the rise in the
aminotransferase serum levels after HD should primarily
occur due to the hemoconcentration induced by the
ultrafiltration; they indicated that this increase could not
be attributed to the removal of inhibitors of the enzymatic
activity of aminotransferases, as previously hypothesized
(17,21). Multicenter studies could potentially confirm the
hypothesis of hemodilution.
Huang et al. evaluated the homocysteine serum levels in
145 patients on HD. All patients had elevated homocysteine
levels, which were inversely related to the AST levels
(r = 0.4; p,0.001). There was no relationship between serum
homocysteine and ALT levels. Thus, the AST serum levels
may reflect the high metabolic activity of homocysteine (25).
To further explore this possibility, a larger group of patients
should be tested.
Some authors raised the possibility that the aminotrans-
ferase serum levels were not related to the dialysis method.
Hung et al. evaluated 90 patients on peritoneal dialysis and
526 healthy adults and reported an average ALT concentra-
tion of 15 IU/L in the peritoneal dialysis patients compared
Figure 1 - Flow chart of article selection performed for the systematic review, 2013.
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with 22 IU/L in the control group (p,0.0001) (26). These
data support the hypothesis that CKD patients have lower
levels of ALT regardless of the dialysis method.
Subsequently, some researchers have suggested that the
aminotransferase serum levels could be reduced even
during conservative treatment at earlier stages of CKD.
Fabrizi et al. evaluated 407 patients with CKD before they
initiated dialysis, 171 patients on dialysis, and 431 healthy
controls and observed that the CKD patients on dialysis
had decreased AST (19.7¡11.2 IU/L vs. 20.4¡6.8 IU/L;
p = 0.00001) and ALT (19.5¡15.1 IU/L vs. 21.7¡11.3 IU/L;
p = 0.00001) serum levels compared with the healthy
controls. Similarly, patients on dialysis had lower amino-
transferase serum levels than CKD patients under con-
servative treatment (AST, 17.9¡8 IU/L vs. 16.6¡11.6 IU/L;
p = 0.01, and ALT 17.9¡8 IU/L vs. 16.3¡9.4 IU/L; p = 0.04,
respectively) (27).
Therefore, CKD patients have reduced aminotransferase
serum levels, and this reduction appears to occur prior to
dialytic treatment.
Gamma glutamyl transferase. Between 1975 and 2012,
we found only three articles about GGT serum levels in
CKD patients on HD without viral hepatitis. In 1975, for the
first time, Fine et al. evaluated GGT serum levels in 32 CKD
patients and reported high levels of this enzyme in 37% of
cases (28).
However, in more recent studies, other authors have
shown that GGT serum levels in CKD patients on HD are
similar to those of patients with normal renal function
(29,30). Fabrizi et al. evaluated GGT serum levels in 573
dialysis patients and 343 healthy patients and reported
average values of 25.8 and 23.3 IU/L, respectively
(p = 0.081). After correcting for sex, race, and age, no
significant difference in GGT levels was observed between
the two groups (30).
In contrast, in light of the hypothesis of hemodilution, our
group evaluated 40 CKD patients on HD and performed
GGT serum dosage immediately prior to and after the
dialysis procedure. When divided by the upper limit of
normal (ULN), the GGT serum levels were 0.88 IU/L prior
to HD and 1.14 after HD (p= 0.001), which is compatible
with the increase in the hematocrit serum levels, thus
characterizing hemoconcentration (Ht before HD, 36.7%;
after HD, 41.3%, p,0.001) (16). Therefore, after the dialysis
procedure, the mean GGT values were higher than those of
the ULN, suggesting that the serum levels of this enzyme
could be reduced in CKD patients prior to the HD session.
Ultimately, GGT serum levels in CKD patients on HD are
not as reduced as the aminotransferase serum levels but are
possibly also influenced by hemodilution due to the liquid
retention of CKD patients.
Liver enzymes in CKD patients on hemodialysis with
viral hepatitis
Aminotransferases. As expected, the CKD patients on
HD infected with HCV have higher aminotransferase serum
levels than those on HD who are not infected (31,35), e.g.,
CKD patients on HD who are also infected with HCV have
lower aminotransferase levels than infected patients who do
not have CKD (36–39).
Cotler et al. evaluated the histological and laboratory data
of 92 patients with HCV (46 renal transplant candidates on
HD and 46 control subjects with normal renal function) and
found that the ALT serum levels were lower (p,0.001) in
the CKD patients on HD than in the controls (40).
The lower aminotransferase levels complicate the proper
assessment and clinical management of HD patients
infected with HCV and hepatitis B virus (HBV) (41,42).
The lower elevation of aminotransferase serum levels in
CKD patients on HD with viral hepatitis could be due to
other factors in addition to those related to CKD alone, as
previously discussed (Figure 2).
One possible factor could be the reduction of viremia as a
result of the dialysis procedure. Tseng et al. evaluated 30
patients infected with the HBV and quantified the viremia
(HBV-DNA) immediately prior to and after the dialysis
session. The average levels of HBV-DNA were higher prior
to the HD session (3.823¡1.130 Log10 copies/mL) than after
it (3.686¡1.114 Log10 copies/mL) (p = 0.004) (42).
Similarly, Baedalamnti et al. evaluated viremia in 11 CKD
patients on HD with HCV infection. The dosages were taken
before, immediately after, and 24 and 48 hours after the
end of the HD session. HCV-RNA levels decreased in all
patients after dialysis (range 3% to 95%, p = 0.001); there-
after, they increased progressively and returned to baseline
at 48 hours after dialysis (before HD session, 824¡234;
immediately after, 633¡178; 24 hours after, 758¡213; and
48 hours after, 776¡226 copies/mL6103). Immediately
after HD, the viral load levels were lower than those prior
to the procedure (p = 0.005) (43).
Additionally, Kaiser et al. evaluated the viremia and
serology of HCV-infected patients during 20 HD sessions
and demonstrated both anti-HCV and HCV-RNA decline
during the dialysis procedure. They also observed that there
was a linear 77% reduction in anti-HCV titers during the
HD session and a 73% reduction of HCV-RNA at the end of
the HD session. However, the reduction in viremia was
observed only in the last two hours of dialysis. These
authors suggested that the serum levels of HCV-RNA and
anti-HCV titers should be regulated or removed indepen-
dently during dialysis and that HD could be a beneficial
therapy when combined with antiviral therapy (44).
Although the dialysis procedure reduces the viral load,
patients on HD infected with HCV may not present lower
viral loads than those with normal renal function. In
evaluating 66 patients on HD infected with HCV and 264
patients also infected but with normal renal function,
Azevedo et al. did not observe any differences in viremia
levels between the two groups (5.36105 IU/mL in the group
on HD and 6.66105 IU/mL in the group with normal renal
function, p= 0.23) (45). Perhaps, the fact that the samples
were collected before hemodialysis session, where the viral
load is higher, has contributed to these findings.
Another factor involved in the reduction of aminotrans-
ferase serum levels could be the increased production of
hepatocyte growth factor (HGF) induced by HD; this
substance stimulates hepatocyte mitogenesis, accelerates
liver regeneration, and protects the liver from toxins (46).
Rampino et al. evaluated 10 HD patients with HCV and
measured HGF before, during (15 min), immediately after,
and 24 hours after the end of dialysis and compared the
results with those from HCV-infected patients who were not
on HD. The HGF serum levels were similar in both groups
prior to the procedure (mean, 0.17 ng/mL). However, after
dialysis, the HGF serum levels increased significantly in
the HD patients compared with patients not on dialysis
(5.51 and 2.67 ng/mL during and after de HD session,
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respectively; p,0.001). It should be noted that even 24 hours
following the procedure, the HGF serum levels of the
patients on HD were higher than those of the patients who
were not on HD (0.41 ng/mL, p,0.05) (46).
Similarly, Baedalamnti et al. evaluated the serum levels
of alpha interferon (IFN-a), a cytokine with antiviral and
immunomodulatory properties, in 11 CKD patients on HD
who had been infected with HCV. The dosages were
performed prior to, immediately after, and 24 and 48 hours
after the end of the HD session. There was a significant rise
in the serum levels of IFN-a in 10 of 11 patients; the values
returned to baseline levels after 48 hours (43). This behavior
suggests that a hemodialysis session induces IFN-a produc-
tion, which could reduce HCV viremia and, consequently,
aminotransferase levels in the serum.
Maia et al. evaluated lymphocyte activation by measuring
the percentages of CD69+ lymphocytes of patients infected
with HCV and on HD; they observed a negative relation-
ship between ALT levels and lymphocyte activation in those
infected with HCV (r = 0.56; p= 0.05). These authors sug-
gested that lymphocyte activation could be a protective
factor against HCV and, therefore, against liver injury (43).
Thus, the increase in IFN-a serum levels and lymphocyte
activation arising from the HD session indicate that CKD
patients on HD who are infected with HCV present a more
pronounced viremia reduction immediately after the session.
Associated with the HGF induction, these patients present an
indolent course of the disease and less severe histological
lesions compared with patients not on HD (38,47,48).
Although biochemical tests are not cost-effective com-
pared with virological tests in detecting new cases of acute
hepatitis C (49), aminotransferases are predictors of the
acute form of hepatitis due to the large increases in their
serum levels in this context (50,51). However, ALT serum
levels are not accurate in the diagnosis of chronic HCV
infection (50). After evaluating 2,440 CKD patients on HD,
Saab et al. demonstrated that a recent rise in ALT serum
levels provided neither sensitivity (21%) nor an adequate
positive predictive value (16%) to diagnose ‘‘chronic’’ HCV
infection (50).
Due to the reduced accuracy of ALT in the diagnosis of
chronic hepatitis in CKD patients on HD, several authors
have sought new cut-off values to improve sensitivity and
specificity and to establish more reliable ALT serum level
values that could be related to histological and virological
activity responses (52,55). To do so, reductions of the ULN
of ALT have been tested to improve their accuracy in
diagnosing aggression against hepatocytes.
After evaluating 202 CKD patients on HD, 15 (7.4%) of
whom were anti-HCV-positive, our group determined that
the cut-off value for ALT stood at 60% of ULN, with a
sensitivity of 67% and specificity of 75% in identifying anti-
HCV-positive patients (54). We observed a similar reduction
when evaluating 217 patients on HD, 18 (8.3%) of whom
were anti-HCV-positive, and 17 (7.8%) of whom were also
HCV-RNA-positive. The cut-off value of ALT to distinguish
the anti-HCV-positive from negative patients was 50% of
the ULN (sensitivity = 67%; specificity = 83%). According to
Figure 2 - Factors involved in aminotransferase reduction in patients with chronic kidney disease on hemodialysis, 2013. *Patients
infected with viral hepatitis. HGF: hepatocyte growth factor; CKD: chronic kidney disease; HD: hemodialysis.
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the HCV-RNA, the cut-off value for ALT was 45% of ULN
with a sensitivity of 71% and a specificity of 80% (53).
Therefore, we concluded that the reduction of the ULN of
ALT could increase the accuracy for the diagnosis of chronic
HCV infection in CKD patients on HD.
Guh et al. performed a study in Taiwan with 217 patients
on HD (including patients with HBV and HCV) and 804
controls and showed that the serum levels of the amino-
transferases could not be used to detect patients with
positive hepatitis B surface antigen (HBsAg). However, the
best cut-off values for detecting the presence of anti-HCV
were 18 IU (40% of the ULN) for AST (sensitivity = 73.8%
and specificity = 55.4%) and 16 IU for ALT (40% of the ULN)
(sensitivity = 61.2% and specificity = 73%). The authors
proposed reductions of 45% for the ULN of AST and 34%
for the ULN of ALT to improve the diagnostic accuracy of
anti-HCV (52).
Caramelo et al. evaluated 22 patients with CKD on HD
with negative anti-HCV and positive HCV-RNA by PCR
and showed that the ALT and AST serum levels may be
useful in the diagnosis of HCV infection in places where the
HCV-RNA survey is not available. These authors used
second-generation enzyme-linked immunosorbent assay
(ELISA) and detected HCV-RNA in 28.2% of the patients
who were negative for anti-HCV. Within the group of
negative anti-HCV patients, the average AST and ALT
values were higher (p,0.001 and p,0.001) in the cases of
positive HCV-RNA than in those with negative HCV-RNA
(56).
Other authors investigated the correlation between
aminotransferases and viremia and demonstrated an asso-
ciation between HCV-RNA and AST and ALT serum levels
(31,37,55,57). Fabrizi et al. demonstrated that patients with
positive HCV-RNA presented higher AST (p,0.008) and
ALT (p,0.0001) serum levels than those observed in HCV-
RNA-negative patients (31). Likewise, Espinosa et al.
demonstrated that ALT serum levels could be predictors
of viremia in CKD patients on HD who are anti-HCV-
positive. In this study, ALT serum levels above 27 IU
showed 50% sensitivity and 100% specificity in the detection
of viremia (57). When Milotic et al. used this same ALT
value, they found differences (p,0.05) between patients
with positive HCV-RNA (40%) and negative HCV-RNA
(9.6%). However, 60% of the patients with positive HCV-
RNA also presented ALT serum levels below 27 IU (55).
Likewise, Fabrizi et al. found that patients infected with
HBV and with positive HBV-DNA presented aminotrans-
ferase serum levels that were higher than the negative
HBV DNA levels: AST 22.8¡31.3 IU/L vs. 14.2¡9.7 IU/L
(p = 0.00001); ALT 25.0¡41.6 IU/L vs. 13.9¡41.6 IU/L
(p = 0.00001) (39).
In contrast, Li et al. evaluated 32 CKD patients on HD
who were anti-HCV-positive. Of these, 12 patients (37.5%)
were HCV-RNA-positive and 20 (62.5%) were negative. The
average ALT serum levels were 15.4¡6.4 IU/L in patients
positive for HCV-RNA and 14.8¡6.4 IU/L in patients
negative for HCV-RNA (p = 0.793), i.e., the presence or
absence of viremia did not affect the ALT serum levels in
CKD patients on HD with anti-HCV (58). The number of
patients in each subgroup of this study was potentially
insufficient to reveal any differences.
As in patients with preserved renal function, aminotrans-
ferases alone did not present any relationship to liver
histology in patients on HD who were infected with HCV
(59,60). However, the degree of hepatic fibrosis can be
estimated using the ratio between the AST serum levels and
the number of platelets (AST-to-Platelet Ratio Index or
APRI). Schiavon et al. evaluated 203 CKD patients on HD
with chronic HCV and found advanced liver fibrosis (F2, F3,
or F4) via the METAVIR classification in 24% of these
patients. The area under the receiver operating character-
istic (ROC) curve for the APRI was 0.81. In patients with an
APRI of less than 0.40, it was reliably possible to identify the
patients with no or mild liver fibrosis (F0 or F1). These
authors stated that, according to the APRI score, approxi-
mately half of the biopsies could have been avoided (61).
These results were also corroborated in a study with 279
patients conducted by Liu et al. in which the APRI could be
used to correctly predict the fibrosis level in 60% of the
patients (62).
Gamma glutamyl transferase. In CKD patients on HD,
GGT serum levels may be a useful and low-cost marker,
similar to aminotransferases, in the diagnosis of chronic
HCV infection (63). However, four articles were found in
the literature regarding GGT serum levels in CKD patients
on HD with viral hepatitis.
Fabrizi et al. identified an association by performing a
multivariate analysis between GGT serum levels and
hepatitis via HBV or HCV. After analyzing the ROC curve,
these authors determined that the best cut-off values to
predict positive HBsAg and anti-HCV would be 23 IU/L
(sensitivity = 62%; specificity = 62%) and 18 IU/L (sensitiv-
ity = 61%; specificity = 50%), respectively. These GGT values
represent ULN reductions of 54% and 64% (50 IU/L) for
the detection of HBsAg and anti-HCV, respectively. The
authors suggested that GGT levels should be measured
monthly for HD patients, as is performed for ALT (30).
Souza et al. also reported higher GGT serum levels in HD
patients with HCV infection than in those negative for anti-
HCV (49.8¡56.6 IU/L and 94.8¡105 IU/L, respectively)
(p,0.05). These authors suggested the use of GGT serum
levels as an indirect marker to detect liver disease in these
patients (64).
In conclusion, patients with CKD on HD have reduced
serum aminotransferase levels. The reasons for this reduc-
tion remain unclear; however, they likely begin before
dialysis and are due in part to hemodilution in patients
before dialysis, lower pyridoxine serum levels, and higher
homocysteine levels.
CKD patients who are on HD and infected with HBV or
HCV also present reduced aminotransferase levels com-
pared with patients with these infections who do not have
CKD. This reduction is due to factors related to CKD and
the reduced viremia caused by dialysis, the production of
HGF and endogenous INF-a, and the lymphocyte activation
induced by HD, which together could decrease viral action
in the liver tissue. However, due to both the small number
of patients evaluated and the specificity of HGF, endogen-
ous INF-a, and lymphocyte activation, further studies are
needed to confirm these hypotheses. Reducing the ULN of
ALT to levels that are approximately 60% of current levels
could more accurately indicate the CKD patients on HD
with viral hepatitis.
There are few studies on GGT serum levels in patients
with CKD undergoing HD, which makes it difficult to draw
further conclusions. The GGT serum levels in CKD patients
on HD are apparently similar to those of patients with
preserved renal function. However, the GGT serum levels
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may be elevated due to the increased oxidative stress
induced by CKD or the use of medications. This increase
would not be as significant due to the reduction in GGT
serum levels induced by hemodilution. As with amino-
transferases, GGT serum levels appear to be useful in the
identification of viral hepatitis during the follow-up of CKD
patients on HD. Nonetheless, further studies are necessary
to better evaluate GGT serum levels in CKD patients on HD.
Finally, it was confirmed that, with or without HCV
infection, serum aminotransferases are reduced in patients
with CKD on HD. Hemodilution is involved in this
reduction; other factors, such as pyridoxine deficiency or
increased homocysteine, may also be involved. In HCV-
infected patients, the serum levels of these enzymes are
potentially decreased due to the reduction of the viral load
that results from the induction of endogenous HGF and
interferons (and the activation of lymphocytes). Further
studies are required to investigate the reduction of HCV
viremia and the involvement of pyridoxine and homocys-
teine in patients with CKD on HD.
The serum aminotransferase levels of are lower in CKD
patients on HD (with or without viral hepatitis) than in
individuals with normal renal function; this difference is
related to factors such as hemodilution, pyridoxine defi-
ciency and hyperhomocysteinemia and, in patients with
viral hepatitis, is associated with HGF elevation, CD69+
lymphocyte induction, and increased interferon-a produc-
tion.
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